Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aclaris Therapeutics, Inc. (ACRS) SEC filings page on Stock Titan provides access to the company’s public filings with the U.S. Securities and Exchange Commission, including current reports on Form 8-K and other key documents referenced in its investor communications. Aclaris is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934.
For ACRS, SEC filings are an important source of information on financial results, clinical development progress, and corporate presentations. Recent Forms 8-K have furnished press releases announcing quarterly and year-to-date financial results, described as including revenue from contract research and licensing, research and development expenses tied to product candidates such as bosakitug, ATI-052 and ATI-2138, and general and administrative costs. Other 8-K filings have furnished R&D Day and corporate overview presentations and detailed top line results from the Phase 2a trial of ATI-2138 in atopic dermatitis.
Through this page, users can locate Aclaris’ current reports that summarize material events, such as updates to its clinical pipeline, conference calls discussing top line clinical data, and investor presentations. While the examples provided are 8-K filings, the SEC Filings page is also the natural place to look for Aclaris’ annual reports on Form 10-K, quarterly reports on Form 10-Q, and any proxy statements or registration statements the company files, which together outline its risk factors, business description, and governance structure.
Stock Titan enhances these filings with AI-powered tools that can help explain complex financial and scientific disclosures in plain language. For ACRS, this can be particularly useful when reviewing detailed discussions of its immuno-inflammatory pipeline, revenue components such as licensing and contract research, and non-cash items like royalty income and contingent consideration revaluations. The page also provides a path to monitor any future insider transaction reports on Form 4 or other ownership-related filings that may be associated with Aclaris’ executive officers and directors.
Aclaris Therapeutics, Inc. furnished an updated corporate overview presentation as part of a current report under Regulation FD. The presentation is attached as Exhibit 99.1 and is also available on the company’s website, providing an overview of its business for investors and other stakeholders. The company states that this material is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings unless specifically referenced.
Biosion, Inc. and its wholly owned subsidiary Bonita Biotech (HK) Limited report their ownership of Aclaris Therapeutics, Inc. common stock on an amended Schedule 13G. Bonita Biotech (HK) Limited holds 11,281,950 shares of common stock, representing 9.4% of the class, with sole voting and dispositive power.
The filing explains that a warrant originally held by Biosion, Inc. for 11,281,985 shares was assigned to Bonita Biotech (HK) Limited on December 9, 2025 and then exercised on a cashless basis, resulting in issuance of 11,281,950 shares on December 15, 2025. The 9.4% figure is based on 119,624,542 shares of Aclaris common stock, which includes 108,342,592 shares outstanding as referenced in a prior Form 8-K and the new shares issued to Bonita Biotech (HK) Limited. The reporting persons certify the shares are not held to change or influence control of Aclaris.
Aclaris Therapeutics (ACRS) reported Q3 2025 results. Total revenue was $3.299 million (contract research $0.485M; licensing $2.814M). Operating expenses rose on pipeline investment, with R&D at $13.028 million and G&A at $4.871 million. The company recorded non‑cash royalty income of $0.716 million from the OLUMIANT royalty sale structure.
Net loss was $14.614 million versus $7.586 million a year ago, reflecting higher development spend. Year‑to‑date, net loss was $45.128 million. The balance sheet showed cash, cash equivalents and marketable securities of $167.2 million as of September 30, 2025, and stockholders’ equity of $120.1 million. Management states its resources are sufficient for more than 12 months from issuance. Shares outstanding were 108,345,239 as of October 31, 2025.
Segment data highlight therapeutics as the primary driver: Q3 R&D included bosakitug $3.062M, ATI‑2138 $1.469M, and ATI‑052 $1.837M, alongside discovery $2.340M. Deferred income related to the royalty sale was $3.925M current and $17.492M non‑current.
Aclaris Therapeutics will host an in-person and virtual R&D Day on October 14, 2025 at 8:00 a.m. ET, with a live webcast available on the Investors Events page. The accompanying company presentation is furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The information in Item 7.01 and Exhibit 99.1 is not deemed “filed” under the Exchange Act or Securities Act, except if expressly incorporated by reference.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
